1. Final Outcomes from the Randomized RECOVERY Trial of Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy
- Author
-
Charles C. Wykoff, Muneeswar G. Nittala, Cecilia Villanueva Boone, Hannah J. Yu, Wenying Fan, Swetha Bindu Velaga, Justis P. Ehlers, Michael S. Ip, SriniVas R. Sadda, Brenda Zhou, Alexander M. Rusakevich, Shaun I.R. Lampen, Sunil K. Srivastava, Jamie L. Reese, Amy Babiuch, Katherine Talcott, Natalia Figueiredo, Sari Yordi, Jenna Hach, William C. Ou, Richard H. Fish, Matthew S. Benz, Eric Chen, Rosa Y. Kim, James C. Major, Ronan E. O’Malley, David M. Brown, Ankoor R. Shah, Amy C. Schefler, Tien P. Wong, Christopher R. Henry, Sagar B. Patel, Vy T. Nguyen, and Kelly L. Larkin more...
- Subjects
Ophthalmology ,Diabetic Retinopathy ,Receptors, Vascular Endothelial Growth Factor ,Recombinant Fusion Proteins ,Intravitreal Injections ,Diabetes Mellitus ,Visual Acuity ,Humans ,Prospective Studies ,Tomography, Optical Coherence - Abstract
Retinal nonperfusion (RNP) is an important biomarker for diabetic retinopathy (DR). Data suggest that consistent anti-VEGF pharmacotherapy can slow RNP development. The RECOVERY trial evaluated the impact of aflibercept (Eylea, Regeneron) on RNP among eyes with proliferative DR (PDR).Prospective, randomized clinical trial with treatment crossover in the second year.Eyes with PDR and RNP.At baseline, the subjects were randomized 1:1 to monthly (arm 1) or quarterly (arm 2) intravitreal 2 mg aflibercept. At the beginning of year 2, the treatment arms were crossed over so that the monthly-dosed subjects subsequently received quarterly dosing and the quarterly-dosed subjects subsequently received monthly dosing.Change in total RNP area (mmAmong all subjects, from baseline to year 2, the mean RNP increased from 235 mmThrough year 2 of the RECOVERY trial, both treatment arms experienced significant increases in RNP. Despite the expansion of the RNP area in nearly all subjects, 82% of subjects demonstrated an improvement in DRSS levels from baseline, with no subjects experiencing worsening in DRSS scores. more...
- Published
- 2022
- Full Text
- View/download PDF